Skip to main content
APhA DrugInfoLine
Sign in to your APhA membership account
Download a PDF of this month's content | Download a PDF of last month's content |Advanced Search
  • HOME
  • NEURO/PSYCH
    • Neurology
    • Psychiatry
  • HEART/LUNGS
    • Cardiology
    • Focus on Lipids Care
    • Focus on Anticoagulation Care
    • Respiratory
    • Focus on Asthma Care
  • GI/KIDNEYS
    • Gastroenterology
    • Nephrology
  • ENDOCRINE/RHEUM
    • Endocrinology
    • Focus on Diabetes Care
    • Rheumatology
  • ID/CANCERS
    • Infectious Diseases
    • Focus on HIV Care
    • Focus on Immunizations
    • Oncology
  • SELF-CARE
    • Alternative Medicines Corner
    • OTC Medicines Corner
  • PERSONALIZED CARE
    • Drug Interactions Corner
    • Pharmacogenomics Corner
  • Endocrine/Rheum
    Endocrinology...
    February 11, 2019

    Cardiovascular risks of fertility treatments

    READ
  • Heart/Lungs
    Focus on Anticoagulat...
    February 11, 2019

    New data support apixaban over rivaroxaban for newly diagnosed VTE

    READ
  • ID/Cancers
    Oncology...
    February 5, 2019

    Treatment outcomes improved in nonmetastatic pancreatic cancer

    READ
  • Neuro/Psych
    Neurology...
    February 5, 2019

    Antiepileptic drugs associated with serious skin reactions

    READ
  • Neuro/Psych
    Psychiatry...
    January 28, 2019

    Off-label use of antipsychotics should be done cautiously in...

    READ
  • Personalized Care
    Drug Interactio...
    January 28, 2019

    Ketogenic diet affects valproic acid, phenobarbital serum...

    READ
  • Heart/Lungs
    Focus on Anticoagulat...
    January 22, 2019

    ASH releases new VTE guidelines

    READ
  • Endocrine/Rheum
    Focus on Diabetes...
    January 22, 2019

    Self-monitoring of blood glucose is not appropriate for everyone

    READ
  • ID/Cancers
    Focus on Immunizations...
    January 15, 2019

    Tdap immunization during third trimester passes on protection to...

    READ
  • GI/Kidneys
    Gastroenterology...
    January 15, 2019

    New guideline on management of opioid-induced constipation

    READ
  • Heart/Lungs
    Cardiology...
    January 7, 2019

    Reduction in heart failure associated with dapagliflozin use

    READ
  • Read more about FDA approves first serotonin-4 receptor agonist for adults with CIC
  • Read more about Biosimilar to trastuzumab approved for patients with HER2-overexpressing breast cancer
  • Read more about Antipsychotics not useful for ICU delirium
  • Read more about Steroid injection an ideal option for first-time carpal tunnel syndrome
  • Read more about FDA approves new formulation of itraconazole for certain systemic fungal infections
  • Read more about I.V. lipid emulsion approved for pediatric patients with parenteral nutrition-associated cholestasis
  • Read more about Quetiapine prescribing decreased after clinicians received Medicare letters
  • Read more about Aspirin may be good for knee replacement thromboembolism prevention
  • Read more about SMART therapy associated with a lower risk of asthma exacerbations
  • Read more about Switching antiepileptic suppliers associated with increased seizure risk?

Medication Monitor

NEW DRUG APPROVALS

  • February 7, 2019
    Caplacizumab-yhdp
    (Cablivi):
    FDA approves first drug therapy for adults with rare blood clotting disorder
  • February 6, 2019
    PrabotulinumtoxinA-xvfs
    (Jeuveau):
    New product approved for 'frown lines'
See more New Drug Approvals

SUPPLEMENTAL APPROVALS

  • February 6, 2019
    Cabozantinib
    (Cabometyx):
    FDA approves cabozantinib tablets for previously treated hepatocellular carcinoma
  • February 1, 2019
    Fluticasone propionate and salmeterol inhalation powder
    (Wixela Inhub):
    FDA approves first generic of Advair Diskus
See more Supplemental Approvals

ALERTS AND RECALLS

  • February 2, 2019
    Test strips
    (CoaguChek XS PT Test Strips):
    FDA issues urgent recall of test strips used to monitor warfarin levels at home
See more Alerts and Recalls

PRODUCT WITHDRAWALS

  • March 26, 2018
    Daclizumab
    (Zinbryta):
    Daclizumab withdrawn after reports of serious inflammatory brain disorders
See more Product withdrawals


                                

Editor's Picks

  • Cardiovascular risks of fertility treatments
  • New data support apixaban over rivaroxaban for...
  • Treatment outcomes improved in nonmetastatic...
  • Antiepileptic drugs associated with serious skin...
  • Off-label use of antipsychotics should be done...

Popular Articles

  • Common antibiotics do not appear to interact with...
  • New oral option for cancer-associated VTE
  • Updated Clostridium difficile guidelines released
  • Pharmacist interventions at black barbershops...
  • New analysis compares efficacy and safety of...

Popular Sections

  • Alerts and Recalls
  • Supplemental Approvals
  • New Drug Approvals
  • Cardiology
  • Alternative Medicines Corner

2215 Constitution Avenue NW, Washington, DC 20037 Telephone 202-628-4410 Fax 202-783-2351

© 2013 American Pharmacists Association All Rights Reserved.

About the American
Pharmacists Association

The American Pharmacists Association (APhA) is the organization whose members are recognized in society as essential in all patient care settings for optimal medication use that improves health, wellness and quality of life. Through information, education and advocacy, APhA empowers its members to improve medication use and advance patient care.

More info

About APhA DrugInfoLine

APhA DrugInfoLine (ISSN 2162-3015) is a weekly publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not neccessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that the information contained in APhA DrugInfoLine is accurate and current; however, they shall have no ability to any person or entity with regard to claims, losses, or damage caused or alleged to be caused, directly or indirectly by use of any information contained in the publication. All decisions about drug therapy must be based on independent judgement of the clinician.

  • Contact Us
  • Section Advisors
  • Terms of Use
  • Privacy Policy